EHA 2026 | Insights into emerging treatment options for Ph+ ALL: TKI and immunotherapy combinations
Ilaria Iacobucci, PhD, St. Jude Children’s Research Hospital, Memphis, TN, discusses recent advancements in treatment options for patients with Ph+ acute lymphoblastic leukemia (ALL). Dr Iacobucci highlights promising results from combining tyrosine kinase inhibitors (TKIs), such as ponatinib, with immunotherapies like blinatumomab, which have led to improved complete remission rates and reduced adverse prognostic markers. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The development of tyrosine kinase inhibitors really revolutionized the outcome of patients with the BCR-ABL Ph-positive ALL and fundamentally changed the historical disease course. However, lately we can see further improvements and specifically the combination of tyrosine kinase inhibitors with immunotherapy-based approaches, especially blinatumomab in combination with ponatinib, has been shown remarkable results in terms of complete remissions, in terms of response regarding the non-adverse prognostic markers...
The development of tyrosine kinase inhibitors really revolutionized the outcome of patients with the BCR-ABL Ph-positive ALL and fundamentally changed the historical disease course. However, lately we can see further improvements and specifically the combination of tyrosine kinase inhibitors with immunotherapy-based approaches, especially blinatumomab in combination with ponatinib, has been shown remarkable results in terms of complete remissions, in terms of response regarding the non-adverse prognostic markers. For example, in the latest study from MD Anderson combining ponatinib and blinatumomab, IKZF1 plus status seems to not have an adverse impact. And the same result has been observed in the latest GIMEMA study where ponatinib was used in induction followed by blinatumomab in consolidation. So remarkable results that are really changing the outcome of patients with Ph-positive ALL.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
